Maybe, but I can't see any reason why he could not have explained that to shareholders.
Ann: SCENESSE European Orphan Drug Designation for VP, page-12
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.92 |
Change
-0.030(0.20%) |
Mkt cap ! $747.1M | |||
| Open | High | Low | Value | Volume |
| $14.91 | $15.19 | $14.71 | $936.9K | 62.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 167 | $14.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 57 | 1 |
View Market Depth
| Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |